Karina Lovell appraises the first UK RCT of computerised cognitive behavioural therapy (cCBT) for depression in children and young people, which shows a clinically meaningful improvement in depression and anxiety.
[read the full story...]
Alex Langford reflects on the media hype surrounding a new RCT of the NAVIGATE intervention; a comprehensive, multidisciplinary, team-based treatment approach for first episode psychosis.
[read the full story...]
Dan-Mikael Ellingsen explores the neurochemistry of placebo effects in major depression, as he reviews a recent study of the association between placebo-activated neural systems and antidepressant responses.
[read the full story...]
Simon Wessely responds to the huge amount of recent criticism that has surrounded the publication of a follow-up paper of the PACE trial into chronic fatigue syndrome. This extended blog presents the PACE trial and its main results, but also reminds us what makes a good RCT, as well as exploring how well PACE measures up.
[read the full story...]
Rachel Brand looks at a recent RCT which investigates the optimal duration of an early intervention in psychosis programme for young people in Hong Kong.
[read the full story...]
Lisa Burscheidt appraises an RCT of telemedicine psychotherapy for depression in older veterans, which establishes non-inferiority of telemedicine delivery versus same-room delivery of behavioural activation.
[read the full story...]
Amy Price and Douglas Badenoch respond to the McPin Foundation talking point paper written by Alison Faulkner entitled ‘Randomised controlled trials: The straitjacket of mental health research?’
[read the full story...]
Ioana Cristea considers the impact that researcher allegiance can have on the conducting and reporting of psychotherapy research.
[read the full story...]
Jill Manthorpe discusses a ‘gold standard’ RCT study on occupational therapy for stroke survivors in UK care homes and the implications of the findings.
[read the full story...]
Lisa Burscheidt summarises a recent randomised controlled trial of combined methylphenidate and citalopram for depression in older people, which presents promising but limited findings.
[read the full story...]
